ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
4.240
+0.190 (4.69%)
Mar 4, 2026, 4:00 PM EST - Market closed
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 7.50, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 76.89% from the current stock price of 4.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 16, 2025.
Analyst Ratings
The average analyst rating for ADC Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +65.09% | Oct 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +135.85% | Aug 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +17.92% | Jun 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +135.85% | Jun 13, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +88.68% | May 15, 2025 |
Financial Forecast
Revenue This Year
81.43M
from 70.84M
Increased by 14.96%
Revenue Next Year
82.30M
from 81.43M
Increased by 1.06%
EPS This Year
-1.42
from -1.62
EPS Next Year
-1.10
from -1.42
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 86.4M | 106.3M | ||||
| Avg | 81.4M | 82.3M | ||||
| Low | 74.3M | 68.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 22.0% | 30.5% | ||||
| Avg | 15.0% | 1.1% | ||||
| Low | 4.9% | -16.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.37 | -0.92 | |
| Avg | -1.42 | -1.10 | |
| Low | -1.45 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.